| | 0h | 1h | 2h | 3h | 4h | 6h | p [#] |
|-----------|------------|------------|---------------|------------------|-------------------|------------|----------------|
| Malaise | 2 (1-3) | 2 (1–2) | 3 (2–3) | 5**** (3–5) | 5**** (4–5) | 1 (1–2) | <0.0001 |
| Shivering | 1 (1-1) | 1 (1-1) | 2 (1–2) | 6**** (3–6) | 4*** (3–6) | 1 (1-1) | <0.0001 |
| Nausea | 1 (1—1) | 1 (1-1) | 1 (1-1) | 1 (1-2) | 2 (1–2) | 1 (1-2) | 0.1002 |
| Headache | 1 (1-1) | 2 (1-2) | 2* (2–4) | 3** (2–5) | 4**** (2–6) | 1 (1-1) | <0.0001 |
| Myalgia | 1 (1-1) | 1 (1-2) | 2 (1-2) | 2** (1–3) | 2** (2–3) | 1 (1-1) | 0.0008 |
| Dizziness | 1 (1-2) | 1 (1-2) | 2 (1-3) | 2 (1-4) | 2 (1-4) | 1 (1-2) | 0.0054 |
| Total | 8 (6–9) | 9 (8–9) | 12 (10–15) | 17*** (14–23) | 19**** (15–22) | 7 (6–8) | <0.0001 |

Additional file 1. Effects of a lipopolysaccharide (LPS) infusion on symptom scores in healthy volunteers (n = 10). LPS was administered as a continuous 4-hour intravenous infusion from 0 to 4h at an infusion rate of 0.5 ng kg⁻¹ hour⁻¹. Volunteer symptoms were evaluated at these time points by means of a modified visual analogue scale, in which each symptom was rated from 1 (implying that the symptom was not present at all) to 10 (implying that the symptom was the worst imaginable). Individual symptom scores were added together to yield a total symptom score with a minimal value of 6 and a maximal value of 60. Data are presented as median (IQR). # p-value for LPS x time interaction (linear mixed model); different from baseline (after Tukey-Kramer adjustment for multiple comparisons), * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.